NRG Therapeutics: Valuation, Funding & Investors
NRG Therapeutics is a neuroscience drug discovery company focused on developing disease-modifying mitochondrial therapeutics aimed at slowing or halting the progression of neurodegenerative disorders such as Parkinson's disease and amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND). The company is pioneering a novel approach by targeting the mitochondrial permeability transition pore (mPTP) to protect neurons, reduce neuroinflammation, and improve motor function. Its lead candidate, NRG5051, has completed IND-enabling studies and is set to enter clinical trials in early 2026. Based in the UK, NRG Therapeutics is supported by a consortium of international life science investors and has received multiple awards to advance its innovative research and development programs.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $67M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $67M
- Latest Funding Round
- Series B
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 08, 2025 | Series B | $67.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Omega Funds | Series B |
| M Ventures | Series B |
| Novartis Venture Fund | Series B |
| SV Health Investors' Dementia Discovery Fund | Series B |
| British Business Bank | Series B |
| Criteria Bio Ventures | Series B |
| Brandon Capital | Series B |
| Parkinson's UK | Series B |
Similar Companies
A snapshot of private companies similar to NRG Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
